Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Arnon Kater
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Principal Investigator - Barbara Eichhorst
Universitätsklinikum Köln
Principal Investigator - Jennifer Brown
Dana Farber Mass General Brigham Cancer Care Inc
Principal Investigator - John Seymour
Peter MacCallum Cancer Ctr
Principal Investigator - Paolo Ghia
OSPEDALE S. RAFFAELE - MILANO
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
170 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
Buenos Aires, Argentina
- Research Site
Buenos Aires, Argentina
- Research Site
Capital Federal, Argentina
- Research Site
Córdoba, Argentina
- Research Site
Adelaide, Australia
- Research Site
Darlinghurst, Australia
- Research Site
Heidelberg, Australia
- Research Site
Kogarah, Australia
- Research Site
Melbourne, Australia
- Research Site
Nedlands, Australia
- Research Site
Waratah, Australia
- Research Site
Woolloongabba, Australia
- Research Site
Krems, Austria
- Research Site
Salzburg, Austria
- Research Site
Vienna, Austria
- Research Site
Goiânia, Brazil
- Research Site
Porto Alegre, Brazil
- Research Site
Porto Alegre, Brazil
- Research Site
Porto Alegre, Brazil
- Research Site
Rio de Janeiro, Brazil
- Research Site
Rio de Janeiro, Brazil
- Research Site
São Paulo, Brazil
- Research Site
São Paulo, Brazil
- Research Site
São Paulo, Brazil
- Research Site
Plovdiv, Bulgaria
- Research Site
Sofia, Bulgaria
- Research Site
Vratsa, Bulgaria
- Research Site
Calgary, Alberta, Canada
- Research Site
Edmonton, Alberta, Canada
- Research Site
Vancouver, British Columbia, Canada
- Research Site
Ottawa, Ontario, Canada
- Research Site
Toronto, Ontario, Canada
- Research Site
Toronto, Ontario, Canada
- Research Site
Montreal, Quebec, Canada
- Research Site
Québec, Quebec, Canada
- Research Site
Beijing, China
- Research Site
Beijing, China
- Research Site
Beijing, China
- Research Site
Changchun, China
- Research Site
Changsha, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 25 Feb 2019
- Primary completion
- 31 Jan 2027
- Completion
- 31 Jan 2027
- Last update posted
- 27 Dec 2024
- Registered enrollment
- 984
- Registry id
- NCT03836261
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.